Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Helix BioPharma ( (TSE:HBP) ) has issued an update.
Helix BioPharma Corp. reported that shareholders overwhelmingly approved all matters at its latest annual general and special meeting, with more than 81% of outstanding shares voted and all four director nominees re-elected by near-unanimous support. Investors also endorsed the reappointment of Clearhouse LLP as auditor and authorized a share consolidation of up to five existing shares for one new share at the board’s discretion, a move that could give the company greater flexibility in managing its capital structure and market positioning as it advances its oncology pipeline.
The most recent analyst rating on (TSE:HBP) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on Helix BioPharma stock, see the TSE:HBP Stock Forecast page.
Spark’s Take on TSE:HBP Stock
According to Spark, TipRanks’ AI Analyst, TSE:HBP is a Neutral.
The score is held down primarily by weak fundamentals—no revenue, ongoing losses, and continued cash burn—partly offset by a stronger balance-sheet position (low leverage) and improving loss/cash-flow trends. Technicals are supportive with the stock above key moving averages, while valuation is difficult to support due to losses and no dividend yield.
To see Spark’s full report on TSE:HBP stock, click here.
More about Helix BioPharma
Helix BioPharma Corp. is a clinical-stage oncology company focused on developing novel therapies for hard-to-treat solid cancers, leveraging a proprietary bio-conjugate platform targeting CEACAM6-expressing tumors. Its lead candidate, L-DOS47, an antibody-enzyme conjugate designed to modify the tumor microenvironment and enhance anti-cancer immunity, has completed Phase Ib trials in non-small cell lung cancer, with additional bi-specific antibody-drug conjugates in discovery.
Average Trading Volume: 2,231
Technical Sentiment Signal: Buy
Current Market Cap: C$172.6M
Learn more about HBP stock on TipRanks’ Stock Analysis page.